What if employers could identify people struggling with obesity earlier on — and prevent some of the major downstream costs associated with those expensive procedures?

There are proven strategies to improve employee health while controlling costs — no matter where you are on the GLP-1 coverage spectrum.  This report expands on the strategies that make up a successful program.

The weight loss craze fueled by highly effective new medicines has forced a big dilemma onto employers: Cover these costly blockbuster drugs and bank on positive outcomes, or withhold paying for the hotly desired treatments for workers and risk backlash.

Dandelion Health used its new clinical AI marketplace to analyze real-world data, showing that GLP-1 drugs may help prevent cardiovascular disease (CVD) for a seven times larger population than previously researched.

Understanding the rapidly changing landscape of GLP-1 medications is key for employers who are looking to control rising Rx costs. 

In this discussion between Garner CEO, Nick Reber, and Chief Research and Data Science Officer, Phil Salinger, you’ll discover the significant impact of GLP-1s on employer health plans, and strategies to address these challenges.